ERBB2 and breast apocrine carcinoma: This case illustrates the favorable outcome of a patient with HER2-positive apocrine breast carcinoma with oligometastatic disease, achieved through a personalized multimodal strategy combining chemotherapy, dual anti-HER2 therapy, surgery, conformal radiotherapy, and SABR.